Clinical Study on the Safety and Efficacy of a Single Intravenous Dose of CRISPR/Cas9-Edited Autologous CD34+ Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Sickle Cell Disease
Latest Information Update: 22 Mar 2024
At a glance
- Drugs BRL 101 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 05 Mar 2024 New trial record